Tango Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $3,181 | $5,392 | $4,117 | $11,607 |
Gross Profit | 2,556 | 5,392 | 4,117 | 11,607 |
EBITDA | -38,193 | -41,908 | -40,290 | -32,256 |
EBIT | -38,818 | -42,530 | -40,910 | -32,878 |
Net Income | -38,853 | -39,876 | -37,670 | -29,167 |
Net Change In Cash | 3,181 | 5,392 | 4,117 | 11,607 |
Free Cash Flow | -37,143 | -41,748 | -36,771 | -33,505 |
Cash | 39,700 | 58,432 | 69,530 | 53,148 |
Basic Shares | 110,540 | 110,301 | 108,683 | 108,507 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $42,069 | $36,527 | $24,860 | $37,042 |
Gross Profit | 42,069 | -78,671 | 24,860 | 37,042 |
EBITDA | -143,096 | -111,758 | -109,463 | -57,293 |
EBIT | -145,595 | -114,173 | -111,071 | -58,190 |
Net Income | -130,302 | -101,744 | -108,176 | -58,235 |
Net Change In Cash | 42,069 | 36,527 | 24,860 | 37,042 |
Cost of Revenue | -81,066 | 114,364 | ||
Free Cash Flow | -132,255 | -119,508 | -116,772 | -61,364 |
Cash | 69,530 | 66,385 | 59,968 | 142,745 |
Basic Shares | 109,226 | 94,572 | 87,820 | 62,108 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.35 |
2025-03-31 | -$0.36 |
2024-12-31 | -$0.34 |
